Evidence map›Paper›PMID 37609171›Full record

ArticlebioRxiv : the preprint server for biology2023

Unleashing the Power of NR4A1 Degradation as a Novel Strategy for Cancer Immunotherapy.

Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Myung-Chul Kim, Yi Liu, Urvi M Patel, Xiangming Li, Donald Shaffer and 6 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 5 countries.

Lei WangDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Yufeng XiaoDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
Yuewan LuoDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Rohan P MasterDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Jiao MoDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Myung-Chul KimDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Yi LiuDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
Urvi M PatelDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Xiangming LiSanofi Oncology, Sanofi, Cambridge, MA 01890.
Donald ShafferSanofi Oncology, Sanofi, Cambridge, MA 01890.
Kevin R GuertinSanofi Integrated Drug Discovery, Sanofi, Cambridge, MA 01890.
Emily MoserDivision of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine, the College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Keiran S SmalleyDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
Daohong ZhouDepartment of Biochemistry & Structural Biology, Center of innovative Drug Discovery, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229.
Guangrong ZhengDepartment of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA.
Weizhou ZhangDepartment of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, FL 32610, USA.
University of Florida · USFlorida State University · USSanofi (United States) · USUniversity of Florida Health · USSanofi (France) · FRThe University of Texas Health Science Center at San Antonio · USUniversity of Copenhagen · DK

Funding

Proteolysis-targeting chimera against BCL-XL inhibits breast cancer metastasisR01CA260239 · NCI · UNIVERSITY OF FLORIDA · PI ZHANG, WEIZHOU · 2021 to 2025
$2.5M
Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapyR01CA290792 · NCI · UNIVERSITY OF FLORIDA · PI Keiran Smalley, Weizhou Zhang · 2024 to 2026
$2.0M
Obesity, inflammation and breast cancerR01CA200673 · NCI · UNIVERSITY OF IOWA · PI ZHANG, WEIZHOU · 2016 to 2020
$1.7M
CD177 suppresses breast-cancer development by inhibiting beta-cateninR01CA203834 · NCI · UNIVERSITY OF IOWA · PI ZHANG, WEIZHOU · 2016 to 2020
$1.7M
NCI NIH HHS R01 CA200673NCI NIH HHS R01 CA203834NCI NIH HHS R01 CA260239NCI NIH HHS R01 CA290792
6 · The paper itself

Abstract

An effective cancer therapy requires both killing cancer cells and targeting tumor-promoting pathways or cell populations within the tumor microenvironment (TME). We purposely search for molecules that are critical for multiple tumor-promoting cell types and identified nuclear receptor subfamily 4 group A member 1 (NR4A1) as one such molecule. NR4A1 has been shown to promote the aggressiveness of cancer cells and maintain the immune suppressive TME. Using genetic and pharmacological approaches, we establish NR4A1 as a valid therapeutic target for cancer therapy. Importantly, we have developed the first-of-its kind proteolysis-targeting chimera (PROTAC, named NR-V04) against NR4A1. NR-V04 effectively degrades NR4A1 within hours of treatment

Indexed as

cancer immunotherapyimmune modulationmelanomaNR4A1PROTAC degrader

Identifiers

PMID37609171
PMCPMC10441411
OpenAlexW4385794340

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.